Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

References

• Löwenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology. 2008;2008:1–11.
   Google Scholar
• Huntly B, Gilliland G, Pathobiology of acute myeloid leukemia. In: Hoffman, editor. Hematology: basic principles and practice; 4th edn. Philadelphia, PA: Churchill Livingstone; 2005. p. 1057–1069.
   Google Scholar
• Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002;62:4955–4962.
   PubMed Web of Science ®Google Scholar
• Gréen H, Falk IJ, Lotfi K, et al. Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics J. 2012;12:111–118.
   PubMed Web of Science ®Google Scholar
• Jakobsen Falk I, Fyrberg A, Paul E, et al. Impact of ABCB1 single nucleotide polymorphisms 1236C > T and 2677G > T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype. Br J Haematol. 2014;167:671–680.
   PubMed Web of Science ®Google Scholar
• He H, Yin J, Li X, et al. Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia. Eur J Clin Pharmacol. 2015;71:293–302.
   PubMed Web of Science ®Google Scholar
• Kim DH, Park JY, Sohn SK, et al. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer. 2006;118:2195–2201.
   PubMed Web of Science ®Google Scholar
• van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, et al. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther. 2006;80:427–439.
   PubMed Web of Science ®Google Scholar
• Hur EH, Lee JH, Lee MJ, et al. C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia. Leuk Res. 2008;32:1601–1604.
   PubMed Web of Science ®Google Scholar
• Hampras SS, Sucheston L, Weiss J, et al. Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia. Int J Mol Epidemiol Genet. 2010;1:201–207.
   PubMedGoogle Scholar
• Scheiner MA, da Cunha Vasconcelos F, da Matta RR, et al. ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients. J Cancer Res Clin Oncol. 2012;138:959–969.
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Rojas L, Herrero MJ, et al. Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015;15:109–118.
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Rojas L, Herrero MJ, et al. Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis. Pharmacogenomics J. 2016;16:1–2.
   PubMed Web of Science ®Google Scholar
• Visscher H, Ross CJ, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30:1422–1428.
   PubMed Web of Science ®Google Scholar
• Yee SW, Mefford JA, Singh N, et al. Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. J Hum Genet. 2013;58:353–361.
   PubMed Web of Science ®Google Scholar
• Müller P, Asher N, Heled M, et al. Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leuk Res. 2008;32:919–929.
   PubMed Web of Science ®Google Scholar
• Tiribelli M, Fabbro D, Franzoni A, et al. Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy. Haematologica. 2013;98:e28–e29.
   PubMedGoogle Scholar
• Wang F, Liang YJ, Wu XP, et al. Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia. Eur J Cancer. 2011;47:1990–1999.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–365.
   PubMed Web of Science ®Google Scholar
• Colovic N, Tomin D, Vidovic A, et al. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia. Biomed Pharmacother. 2012;66:578–582.
   PubMed Web of Science ®Google Scholar
• Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80:27–38.
   Web of Science ®Google Scholar
• Lal S, Wong ZW, Sandanaraj E, et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99:816–823.
   PubMed Web of Science ®Google Scholar
• Cortez MA, Scrideli CA, Yunes JA, et al. mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death. Pediatr Blood Cancer. 2009;53:996–1004.
   PubMed Web of Science ®Google Scholar
• Siegsmund M, Brinkmann U, Scháffeler E, et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol. 2002;13:1847–1854.
   PubMed Web of Science ®Google Scholar
• Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an adult AIDS clinical trials group collaboration. Clin Infect Dis. 2006;43:783–786.
   PubMed Web of Science ®Google Scholar
• Damiani D, Michieli M, Ermacora A, et al. Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. Leukemia. 1998;12:1236–1240.
   PubMed Web of Science ®Google Scholar
• Ulzurrun E, Stephens C, Ruiz-Cabello F, et al. Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort. PLoS One. 2014;9:e94675.
   PubMed Web of Science ®Google Scholar
• van der Holt B, Löwenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood. 2005;106:2646–2654.
   PubMed Web of Science ®Google Scholar
• Schaich M, Soucek S, Thiede C, et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukemia. Br J Haematol. 2005;128:324–332.
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112:3754–3762.
   PubMed Web of Science ®Google Scholar
• Vulsteke C, Lambrechts D, Dieudonné A, et al. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol. 2013;24:1513–1525.
   PubMed Web of Science ®Google Scholar
• Ross DD, Karp JE, Chen TT, et al. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood. 2000;96:365–368.
   PubMed Web of Science ®Google Scholar
• Benderra Z, Faussat AM, Sayada L, et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res. 2004;10:7896–7902.
   PubMed Web of Science ®Google Scholar
• Damiani D, Tiribelli M, Calistri E, et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica. 2006;91:825–828.
   PubMed Web of Science ®Google Scholar
• Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther. 2002;1:611–616.
   PubMed Web of Science ®Google Scholar
• Meissner K, Heydrich B, Jedlitschky G, et al. The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. J Histochem Cytochem. 2006;54:215–221.
   PubMed Web of Science ®Google Scholar
• Scheffer GL, Pijnenborg AC, Smit EF, et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol. 2002;55:332–339.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Tsuji D, Yamamoto K, et al. Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. Drug Metab Pharmacokinet. 2015;30:149–153.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Im SA, Keam B, et al. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci. 2015;106:86–93.
   PubMed Web of Science ®Google Scholar
• Kim KP, Ahn JH, Kim SB, et al. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Cancer Chemother Pharmacol. 2012;69:1221–1227.
   PubMed Web of Science ®Google Scholar
• Takakuwa O, Oguri T, Uemura T, et al. ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia. Anticancer Res. 2014;34:3517–3522.
   PubMed Web of Science ®Google Scholar